TW202400148A - 作為trpa1抑制劑之吡啶酮化合物 - Google Patents
作為trpa1抑制劑之吡啶酮化合物 Download PDFInfo
- Publication number
- TW202400148A TW202400148A TW112116368A TW112116368A TW202400148A TW 202400148 A TW202400148 A TW 202400148A TW 112116368 A TW112116368 A TW 112116368A TW 112116368 A TW112116368 A TW 112116368A TW 202400148 A TW202400148 A TW 202400148A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- cycloalkyl
- compound
- pharmaceutically acceptable
- tautomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338181P | 2022-05-04 | 2022-05-04 | |
| US63/338,181 | 2022-05-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202400148A true TW202400148A (zh) | 2024-01-01 |
Family
ID=88647177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112116368A TW202400148A (zh) | 2022-05-04 | 2023-05-03 | 作為trpa1抑制劑之吡啶酮化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250270198A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4519250A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515096A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119451948A (cg-RX-API-DMAC7.html) |
| AR (1) | AR129212A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250397A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400148A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215775A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025167992A1 (zh) * | 2024-02-08 | 2025-08-14 | 宜昌人福药业有限责任公司 | 一种非选择性阳离子通道trpa1拮抗剂及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060488A1 (en) * | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2022056042A1 (en) * | 2020-09-09 | 2022-03-17 | University Of Virginia Patent Foundation | Inhibitors of spinster homolog 2 (spns2) for use in therapy |
| CA3211048A1 (en) * | 2021-04-14 | 2022-10-20 | Boehringer Ingelheim International Gmbh | 3h,4h,5h,6h,7h-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as trpa1 inhibitors |
| US20250136587A1 (en) * | 2022-02-03 | 2025-05-01 | D. E. Shaw Research, Llc | N3-substituted uracil compounds as trpa1 inhibitors |
-
2023
- 2023-05-03 WO PCT/US2023/066533 patent/WO2023215775A1/en not_active Ceased
- 2023-05-03 TW TW112116368A patent/TW202400148A/zh unknown
- 2023-05-03 JP JP2024564931A patent/JP2025515096A/ja active Pending
- 2023-05-03 AR ARP230101074A patent/AR129212A1/es unknown
- 2023-05-03 US US18/862,249 patent/US20250270198A1/en active Pending
- 2023-05-03 EP EP23800196.0A patent/EP4519250A4/en active Pending
- 2023-05-03 CA CA3250397A patent/CA3250397A1/en active Pending
- 2023-05-03 CN CN202380048290.4A patent/CN119451948A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4519250A1 (en) | 2025-03-12 |
| CN119451948A (zh) | 2025-02-14 |
| EP4519250A4 (en) | 2026-01-14 |
| WO2023215775A1 (en) | 2023-11-09 |
| AR129212A1 (es) | 2024-07-31 |
| US20250270198A1 (en) | 2025-08-28 |
| CA3250397A1 (en) | 2023-11-09 |
| JP2025515096A (ja) | 2025-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6948659B1 (ja) | ピリダジニルチアアゾールカルボキシアミド化合物 | |
| JP7189956B2 (ja) | Sos1阻害剤としての新規なベンジルアミノ置換ピリドピリミジノンおよび誘導体 | |
| JP6745856B2 (ja) | Fgfr4阻害剤としての縮環二環式ピリジル誘導体 | |
| JP7397452B2 (ja) | ヘテロアリールカルボキシアミド化合物 | |
| EP3555063B1 (en) | 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors | |
| JP6289485B2 (ja) | Pde4のヘテロアリール阻害剤 | |
| JP2024020220A (ja) | 免疫調節剤としての複素環式化合物 | |
| KR20190012167A (ko) | 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도 | |
| TW202342465A (zh) | 作為trpa1抑制劑之n3經取代脲嘧啶化合物 | |
| TW202334167A (zh) | 作為erbb2抑制劑之稠合四環喹唑啉衍生物 | |
| CA2922044A1 (en) | Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk) | |
| TW202339720A (zh) | 作為trpa1抑制劑之噠嗪酮化合物 | |
| CN119451948A (zh) | 作为trpa1抑制剂的吡啶酮化合物 | |
| TW202214634A (zh) | 雜環化合物及其衍生物 | |
| TW202440084A (zh) | 作為trpa1抑制劑之雙環醯亞胺化合物 | |
| TW202515569A (zh) | 雙環及單環trpa1抑制劑 | |
| TWI690528B (zh) | 稠環雙環吡啶基衍生物 | |
| HK40118929A (en) | N3-substituted uracil compounds as trpa1 inhibitors | |
| KR20190132703A (ko) | 선택적 NK-3 수용체 길항제로서의 신규한 키랄 N-아실-5,6,7,(8-치환된)-테트라히드로-[1,2,4]트리아졸로[4,3-a]피라진, 의약 조성물, NK-3 수용체 매개 질환에 사용하는 방법 및 그의 키랄 합성법 |